---
title: 'Influence of adjuvant therapies on organ-specific recurrence of cutaneous
  melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry
  ADOReg'
date: '2024-07-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38975881/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240708183216&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: This study investigated whether adjuvant treatments in stage III cutaneous
  melanoma (CM) influenced patterns of recurrence. Patients with primary (n = 1033)
  or relapsed CM (n = 350) who received adjuvant therapies with Nivolumab (N), Pembrolizumab
  (P), or Dabrafenib and Trametinib (D + T) were extracted from the prospective multicenter
  real-world skin cancer registry ADOReg. Endpoints were progression-free survival
  (PFS), distant metastasis-free survival (DMFS), organ-specific DMFS, and ...
disable_comments: true
---
This study investigated whether adjuvant treatments in stage III cutaneous melanoma (CM) influenced patterns of recurrence. Patients with primary (n = 1033) or relapsed CM (n = 350) who received adjuvant therapies with Nivolumab (N), Pembrolizumab (P), or Dabrafenib and Trametinib (D + T) were extracted from the prospective multicenter real-world skin cancer registry ADOReg. Endpoints were progression-free survival (PFS), distant metastasis-free survival (DMFS), organ-specific DMFS, and ...